NovaBridge Biosciences (NBP) Notes Payables (2018 - 2023)

NovaBridge Biosciences (NBP) has 4 years of Notes Payables data on file, last reported at $4.2 million in Q4 2023.

• Notes Payables for Q4 2023 came in at $4.2 million, up 56.17% year-over-year; the trailing twelve-month figure through Dec 2023 was $4.2 million (up 56.17% YoY), and the FY2023 annual result was $4.2 million, down 99.85% from the prior year.
• Notes Payables advanced to $4.2 million in Q4 2023 per NBP's latest filing, from $4.1 million in the prior quarter.
• Over five years, Notes Payables peaked at $7.1 million in Q4 2019 and troughed at $2.7 million in Q4 2022.
• A 3-year average of $4.5 million and a median of $4.1 million in 2023 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2019 and 2023: Notes Payables tumbled 38.69% in 2019, then jumped 56.17% in 2023.
• A 3-year view of Notes Payables shows it stood at $7.1 million in 2019, then tumbled by 62.43% to $2.7 million in 2022, then jumped by 56.17% to $4.2 million in 2023.
• Business Quant data shows NBP's Notes Payables at $4.2 million in Q4 2023, $4.1 million in Q2 2023, and $2.7 million in Q4 2022.